Growth
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
New Science As A Business Growth Strategy
Finding innovative ways to adapt the biopharma business model to external and internal challenges is a key competitive differentiator for today’s C-suite leadership.
Latest From Growth
Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Changing China Is Opening Up For Health Care Entrants
The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.
Taking Aim At Advanced Therapies
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.
Denmark Offers One-Stop-Shop For Clinical Trials
Denmark’s Trial Nation Portal was established in 2018 with government backing and the aim of luring clinical trials to the country.
PureTech’s Problem-Solving Skills Target The BIG Picture
PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.
MorphoSys: A European Champion Crossing The Biopharma Rubicon
The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.